Human trials of third homegrown COVID-19 vaccine to begin in March

The highest dose, 75mcg, of Nanocovax was given to three volunteers in Hanoi on January 12. (Photo: MoH)

Hanoi (VNA) – A third vaccine
developed by Vietnam is scheduled to be tested on humans at the end of March,
the said on January 19.

The vaccine is developed by Vaccine and Biological
Production No. 1 (). It is one of the four companies that are developing
COVID-19 vaccines in Vietnam, along with the Institute of Vaccines and Medical
Biologicals (IVAC), the Centre for Research and Production of Vaccines and
Biologicals (POLYVAC), and Nanogen Pharmaceutical Biotechnology (NANOGEN).

Nanocovax by NANOGEN is Vietnam’s first candidate
vaccine against the novel coronavirus SARS-CoV-2 to reach the human trial
stage.

The highest dose, 75mcg, of Nanocovax was given to
three volunteers in Hanoi on January 12.

The Nha Trang-based has also been authorised to
carry out human clinical tests for its Covivac.

According to Associate Professor Dr Chu Van Men,
Director of the Military Medical University’s Centre for Clinical Trials and
Bioequivalence, Vietnam expects to collect all necessary data on clinical
testing by the end of 2021 before it can consider mass vaccination./.